Product Name: CDK6 (10-16) pY13
Product Number: PE-04AJP95
Size: 200 µg      Price:47.00
1 mg      $US94.00
5 mg      206.00
Peptide Name: CDK6 (10-16) pY13

Product Use: Services as a blocking peptide for use with the CDK6-pY13 rabbit polyclonal antibody (Cat. No.: AB-PK571) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain in subdomain I, which is involved in binding the phosphates in the ATP substrate. Phosphorylation inhibits phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: DQQ-pY-ECV

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1138.09 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: CDK6 - pY13 phosphosite-specific antibody (Cat. No.: AB-PK571)

Scientific Background: CDK6 is a protein-serine/threonine kinase of the CMGC group and CDK family. It is involved in cell cycle regulation and differentiation, which promotes G1/S transition. Phosphorylation at T177 increases phosphotransferase activity. Germline mutations in CDK6 are hypothesized to lead to a predisposition to melanoma. A197T mutation is found in family with autosomal recessive primary microcephaly-12 (MCPH12).